Melacine

Melacine

An allogeneic melanoma tumour cell lysate combined with the adjuvant Detox, which was used as an anti-tumour vaccine and had some (minimal) benefit for advanced and metastatic melanoma, and in melanoma patients who expressed HLA-I A2 and/or HLA-C3.
References in periodicals archive ?
Rechtman, "A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma," Canadian Journal of Infectious Diseases and Medical, vol.
Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol 2003;13:409-15.
For example, M-Vax, OncoVax and Melacine, the first three therapeutic vaccines to reach the international market, have all sold poorly as each has been launched in only a small number of nations.
-- The manufacturer of the Melacine melanoma vaccine is planning to finalize plans for a second pivotal trial of the vaccine in people with stage II disease.
-- The manufacturer of the Melacine melanoma vaccine plans to finalize plans for a second, pivotal trial of the vaccine in people with intermediate-thickness stage II disease, now that a Food and Drug Administration expert panel has agreed to the proposed study design.
On February 15, Corixa and Schering Canada, a wholly owned subsidiary of Schering-Plough Corporation, announced the immediate availability in Canada of Corixa's Melacine vaccine, a therapeutic vaccine for treatment of Stage IV melanoma.
Corixa Corporation (Nasdaq:CRXA), a research and development-based biotechnology company, has released additional data from its Phase III, randomized trial to evaluate Corixa's therapeutic vaccine Melacine, for the treatment of Stage II melanoma.
Sosman of the University of Illinois at Chicago reported results indicating that the clinical benefit of Melacine vaccination was significantly higher in patients with specific human leukocyte antigen (HLA) phenotypes.
The Phase III clinical trial was conducted by the Southwest Oncology Group with the primary study endpoint being the comparison of disease-free survival in 689 total patients with Stage II melanoma who, following surgical removal of the patient's primary tumor, received adjuvant immunotherapy with Melacine vaccine, versus no adjuvant therapy.
New data on the relationship of the HLA phenotype of the patients to their response to Melacine vaccine were presented.
Initial Phase III data was presented by the Southwest Oncology Group, indicating that Corixa's Melacine vaccine prolonged disease free survival in patients following surgery for Stage II melanoma and in particular for those patients with thinner (smaller) tumors.
One bright spot, though, is a new melanoma vaccine, called Melacine. It utilizes components of melanoma that are injected into a patient, hoping the immune system will develop the antibodies necessary to fight off the illness.